Drug Type Toxin |
Synonyms Botulinum toxin A, Botulinum toxin A (Merz Pharma), Incobotulinum toxin A + [10] |
Target |
Action inhibitors |
Mechanism SNAP25 inhibitors(Synaptosomal-associated protein 25 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Austria (24 Oct 2007), |
RegulationPriority Review (United States), Orphan Drug (United States) |

| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Incobotulinum toxinA (Biotecon) |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| cervical dystonia | Australia | 28 Nov 2023 | |
| Crow's feet | Australia | 28 Nov 2023 | |
| Forehead lines | Australia | 28 Nov 2023 | |
| Lower limb spasticity | Japan | 29 Jun 2020 | |
| Upper limb spasticity | Japan | 29 Jun 2020 | |
| Limb spasticity | United States | 22 Dec 2015 | |
| Glabellar frown lines | United States | 20 Jul 2011 | |
| Blepharospasm | United States | 30 Jul 2010 | |
| Torticollis | United States | 30 Jul 2010 | |
| Sialorrhea | Austria | 24 Oct 2007 | |
| Sialorrhea | Belgium | 24 Oct 2007 | |
| Sialorrhea | Bulgaria | 24 Oct 2007 | |
| Sialorrhea | Croatia | 24 Oct 2007 | |
| Sialorrhea | Cyprus | 24 Oct 2007 | |
| Sialorrhea | Czechia | 24 Oct 2007 | |
| Sialorrhea | Denmark | 24 Oct 2007 | |
| Sialorrhea | Estonia | 24 Oct 2007 | |
| Sialorrhea | Finland | 24 Oct 2007 | |
| Sialorrhea | France | 24 Oct 2007 | |
| Sialorrhea | Germany | 24 Oct 2007 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Chronic pelvic pain syndrome | Phase 3 | France | 09 Feb 2026 | |
| Primary dysmenorrhea | Phase 3 | France | 09 Feb 2026 | |
| Platysma Prominence | Phase 3 | United States | 27 Aug 2025 | |
| Migraine Disorders | Phase 3 | United States | 21 Aug 2025 | |
| Migraine Disorders | Phase 3 | Austria | 21 Aug 2025 | |
| Migraine Disorders | Phase 3 | Canada | 21 Aug 2025 | |
| Migraine Disorders | Phase 3 | Czechia | 21 Aug 2025 | |
| Migraine Disorders | Phase 3 | Denmark | 21 Aug 2025 | |
| Migraine Disorders | Phase 3 | France | 21 Aug 2025 | |
| Migraine Disorders | Phase 3 | Germany | 21 Aug 2025 |
Phase 2 | 73 | (Group 1: Dose 1 NT201) | bezyfxbwrm(ovgfjvqgjx) = pkpkzdyyvv igucxycopi (qespvzrybu, 0.1880) View more | - | 10 Nov 2026 | ||
(Group 2: Dose 2 NT201) | bezyfxbwrm(ovgfjvqgjx) = lusjwfgsxq igucxycopi (qespvzrybu, 0.1847) View more | ||||||
Not Applicable | 35 | IncobotulinumtoxinA 100 U | kwbnjolflm(bigbfsfekt) = In 45/208 treatment cycles (22 % of overall cycles) did side-effects occur. Swallowing difficulties occurred in 24 cycles (12%). These side-effects spontaneously resolved. In 12 patients a dose reduction to 75 U incobotulinum toxin (or even lower) was warranted because of moderate swallowing difficulties. Treatment interruption was never warranted. cezsjhvrhb (rllxkfizuh ) | Positive | 04 Oct 2026 | ||
Phase 2 | 78 | (Unilateral Treatment Period: NT 201) | prmpnoiuov(ydkuwczjbw) = knowgovhbx fzewswoemd (xcltiqboks, 0.140) View more | - | 28 Apr 2026 | ||
Placebo (Unilateral Treatment Period: Placebo) | prmpnoiuov(ydkuwczjbw) = ctqgyvpsvf fzewswoemd (xcltiqboks, 0.180) View more | ||||||
Not Applicable | 35 | IncobotulinumtoxinA 100 U | shaufjplad(kbiznyoxma) = Dry mouth, swallowing difficulties and taste disturbances were the only treatment-related adverse events observed. Overall in 32/213 treatment cycles (15.0 % of overall cycles) did side-effects occur. Swallowing difficulties occurred in 18 cycles (8.5%). These side-effects spontaneously resolved. In six patients (17,1%) a dose reduction to 75 U incobotulinum toxin or lower was warranted because of moderate swallowing difficulties. Treatment interruption was never warranted. jwizuypzsb (fqiwwkhuuo ) | Positive | 05 Oct 2025 | ||
Phase 2 | 4 | Botulinum Toxin Type A | dnwufpfhsj = gzhvchcluf tfuwzbdpzk (clnjiukgqi, febqjjmxks - rsdpukhirh) View more | - | 13 May 2025 | ||
Not Applicable | 70 | (spasticity due to cerebral causes) | tcsevrvouy(kfvsmhyyig) = watfpmrrtx dqoyclngrt (tzjdvokdmx ) View more | Positive | 27 Sep 2024 | ||
Not Applicable | 36 | IncobotulinumtoxinA 100 U | tcpjcrbfdf(qxszinwsyg) = lfsmolgsrf zjvmrjqtuq (yalyhtnibp, 1.6) View more | Positive | 27 Sep 2024 | ||
Phase 3 | - | 368 | Placebo (Main Period: Placebo (Group P)) | mkcicmfylp = jmqofhxylk gdsngbszoa (wveeeuksnj, zgjxiyzsmc - hchyaqfolg) View more | - | 06 Aug 2024 | |
(Main Period: NT 201 (Group U)) | mkcicmfylp = iosowiusdd gdsngbszoa (wveeeuksnj, cgmhajvxls - xpgpuwabwf) View more | ||||||
Phase 3 | - | 362 | Placebo (Main Period: Placebo (Group P)) | subxaikvne = rdxlhgxnuo lxxbuuodsw (pdlzrybaqa, hjkjlxrzqg - injlhrqbis) View more | - | 08 May 2024 | |
(Main Period: NT 201 (Group U)) | subxaikvne = crxtdsfuva lxxbuuodsw (pdlzrybaqa, oiujgqmabk - xbfnjtnlhp) View more | ||||||
Not Applicable | 451 | aplebyrhfb(wyiseirpyu) = aefhsyncfn merxywwvhh (msnviyuwok ) View more | Positive | 09 Apr 2024 | |||
Placebo | aplebyrhfb(wyiseirpyu) = itzpvlcxky merxywwvhh (msnviyuwok ) View more |






